دورية أكاديمية
أعرض في EDS

Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity.

التفاصيل البيبلوغرافية
العنوان: Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity.
المؤلفون: Ma R; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA; Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA; William T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Woods M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Burkhardt P; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA; Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA., Crooks N; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., van Leeuwen DG; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA; Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA., Shmidt D; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Couturier J; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Chaumette A; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Popat D; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Rouce RH; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Thakkar S; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Orozco AF; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA., Carisey AF; William T. Shearer Center for Human Immunobiology, Texas Children's Hospital, Houston, TX 77030, USA., Brenner MK; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA; Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Mamonkin M; Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA; Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: mamonkin@bcm.edu.
المصدر: Cell reports. Medicine [Cell Rep Med] 2024 Jul 16; Vol. 5 (7), pp. 101628. Date of Electronic Publication: 2024 Jul 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, [2020]-
مواضيع طبية MeSH: CD5 Antigens*/metabolism , Receptors, Chimeric Antigen*/metabolism , Receptors, Chimeric Antigen*/immunology, Humans ; Cytotoxicity, Immunologic ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Immunotherapy, Adoptive/methods ; Animals ; Receptors, Antigen, T-Cell/metabolism ; Receptors, Antigen, T-Cell/immunology
مستخلص: Chimeric antigen receptor T cells (CART) targeting lymphocyte antigens can induce T cell fratricide and require additional engineering to mitigate self-damage. We demonstrate that the expression of a chimeric antigen receptor (CAR) targeting CD5, a prominent pan-T cell antigen, induces rapid internalization and complete loss of the CD5 protein on T cells, protecting them from self-targeting. Notably, exposure of healthy and malignant T cells to CD5.CART cells induces similar internalization of CD5 on target cells, transiently shielding them from cytotoxicity. However, this protection is short-lived, as sustained activity of CD5.CART cells in patients with T cell malignancies results in full ablation of CD5 + T cells while sparing healthy T cells naturally lacking CD5. These results indicate that continuous downmodulation of the target antigen in CD5.CART cells produces effective fratricide resistance without undermining their on-target cytotoxicity.
Competing Interests: Declaration of interests M.M. and M.K.B. are co-founders of March Biosciences, have equity, and serve on the advisory board for March Biosciences. M.K.B. is a cofounder and equity holder in AlloVir, Inc. and Marker Therapeutics. M.K.B. has equity in Tessa Therapeutics Ltd. and March Biosciences and serves on advisory boards for Marker Therapeutics, Allogene, Walking Fish, Abintus, Tessa Therapeutics, Athenex, ONK Therapeutics, Coya Therapeutics, Triumvira, Adaptimmune, Vor Therapeutics, and TScan. M.M. serves on the scientific advisory board of NKILT and receives research support from Fate Therapeutics and honoraria from Amgen and Galapagos NV. L.C.H. provides consulting services to March Biosciences. M.M. and M.K.B. have patent applications and a granted patent related to this work. An up-to-date declaration of interests for the listed authors can be found at https://www.bcm.edu/academic-centers/cell-and-gene-therapy/research/disclosure-of-outside-interests.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
References: Blood Adv. 2023 Aug 22;7(16):4418-4430. (PMID: 37171449)
Blood. 2017 Jul 20;130(3):285-296. (PMID: 28539325)
Nat Med. 2018 Jan;24(1):20-28. (PMID: 29155426)
Br J Haematol. 2013 Oct;163(2):182-93. (PMID: 23927424)
Blood. 2024 Mar 28;143(13):1231-1241. (PMID: 38145560)
Nat Med. 2018 Oct;24(10):1499-1503. (PMID: 30275568)
Cancer Discov. 2015 Dec;5(12):1282-95. (PMID: 26516065)
Leukemia. 2021 Dec;35(12):3466-3481. (PMID: 34035409)
Front Immunol. 2020 Jun 05;11:1128. (PMID: 32582204)
Blood. 2010 Mar 25;115(12):2420-9. (PMID: 20089966)
Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2216352120. (PMID: 36598945)
Cancer Immunol Res. 2022 Apr 1;10(4):498-511. (PMID: 35362043)
Genome Biol. 2020 Jul 30;21(1):188. (PMID: 32731885)
Exp Cell Res. 1989 May;182(1):114-28. (PMID: 2785456)
Nat Commun. 2020 Feb 7;11(1):798. (PMID: 32034142)
Clin Exp Immunol. 1991 Dec;86(3):506-13. (PMID: 1747958)
J Biochem Biophys Methods. 1995 Nov;30(4):249-55. (PMID: 8621884)
N Engl J Med. 2018 Jul 5;379(1):64-73. (PMID: 29972754)
J Clin Invest. 2010 Nov;120(11):3869-77. (PMID: 20978348)
J Immunol. 2002 Jun 1;168(11):5612-20. (PMID: 12023358)
Blood. 2023 Mar 9;141(10):1194-1208. (PMID: 36044667)
J Immunol. 2001 Jan 1;166(1):396-402. (PMID: 11123317)
Front Oncol. 2019 Mar 05;9:126. (PMID: 30891427)
Mol Ther. 2017 Sep 6;25(9):2189-2201. (PMID: 28676342)
Nat Biotechnol. 2022 Feb;40(2):245-253. (PMID: 34594043)
Eur J Immunol. 2002 Jun;32(6):1811-7. (PMID: 12115665)
Br J Haematol. 1988 Nov;70(3):289-94. (PMID: 3264717)
J Immunother Cancer. 2022 Nov;10(11):. (PMID: 36323436)
Blood Adv. 2017 Nov 21;1(25):2348-2360. (PMID: 29296885)
J Immunol. 2015 Feb 1;194(3):911-20. (PMID: 25520398)
Biochem Biophys Res Commun. 2010 Feb 19;392(4):500-4. (PMID: 20085752)
Blood. 2022 Jul 28;140(4):321-334. (PMID: 35500125)
Mol Ther. 2017 Aug 2;25(8):1946-1958. (PMID: 28506593)
Cancer Immunol Res. 2018 Jan;6(1):47-58. (PMID: 29079655)
Blood. 2017 Dec 28;130(26):2838-2847. (PMID: 29089311)
J Genet Genomics. 2019 Aug 20;46(8):367-377. (PMID: 31466926)
Leukemia. 2019 Dec;33(12):2854-2866. (PMID: 31110217)
J Clin Invest. 2019 Mar 21;129(6):2210-2221. (PMID: 30896447)
JCI Insight. 2018 Jul 12;3(13):. (PMID: 29997304)
Nat Biotechnol. 2021 Jan;39(1):56-63. (PMID: 32661440)
Blood. 2015 Aug 20;126(8):983-92. (PMID: 26056165)
Mol Cell Biol. 2018 Oct 15;38(21):. (PMID: 30104252)
J Clin Invest. 2020 Sep 1;130(9):4652-4662. (PMID: 32437331)
J Immunol. 2007 Jun 1;178(11):6821-7. (PMID: 17513730)
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. (PMID: 29812997)
Mol Cell Biol. 1999 Apr;19(4):2903-12. (PMID: 10082557)
Blood. 1991 Sep 1;78(5):1173-82. (PMID: 1878584)
Blood. 1986 Sep;68(3):752-61. (PMID: 3488778)
J Clin Invest. 2015 Jan;125(1):157-68. (PMID: 25415440)
Mol Imaging Biol. 2011 Jun;13(3):526-535. (PMID: 20628903)
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8810-4. (PMID: 1978939)
Cancer Res. 2022 Jul 18;82(14):2610-2624. (PMID: 35294525)
J Biomech. 2010 May 28;43(8):1598-602. (PMID: 20185133)
Mol Ther. 2023 Jan 4;31(1):24-34. (PMID: 36086817)
Methods Mol Biol. 2020;2086:119-130. (PMID: 31707671)
Sci Signal. 2021 Aug 24;14(697):. (PMID: 34429382)
J Immunol. 2011 Jul 1;187(1):102-9. (PMID: 21622855)
Nature. 2019 Apr;568(7750):112-116. (PMID: 30918399)
Stem Cell Rev Rep. 2019 Jun;15(3):443-447. (PMID: 30826931)
Hum Gene Ther. 2013 Mar;24(3):295-305. (PMID: 23297870)
Blood. 1992 Mar 15;79(6):1511-7. (PMID: 1372189)
فهرسة مساهمة: Keywords: CAR; CD5; T cell fratricide; T cell malignancies; chimeric antigen receptor; clinical trials; fratricide; off-tumor toxicity
المشرفين على المادة: 0 (CD5 Antigens)
0 (Receptors, Chimeric Antigen)
0 (Receptors, Antigen, T-Cell)
تواريخ الأحداث: Date Created: 20240710 Date Completed: 20240717 Latest Revision: 20240816
رمز التحديث: 20240816
مُعرف محوري في PubMed: PMC11293353
DOI: 10.1016/j.xcrm.2024.101628
PMID: 38986621
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-3791
DOI:10.1016/j.xcrm.2024.101628